Web Exclusives

Updated analysis of IKEMA showed improved responses with isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Read More ›

Ciltacabtagene autoleucel has been shown to have compelling survival benefit, and a new study shows improved health-related quality of life in patients with triple-class exposed multiple myeloma. Read More ›

Final analysis of ICARIA-MM supports isatuximab plus pomalidomide and dexamethasone as standard of care in patients with relapsed/refractory multiple myeloma. Read More ›

Continuing medical education and nursing continuing professional development–approved activities can improve clinicians’ knowledge of the fast-emerging treatment landscape in multiple myeloma. Read More ›

Daratumumab plus lenalidomide and dexamethasone showed deep clinical responses in patients who continued treatment for ≥18 months. Read More ›

Final results from the LYRA study demonstrate daratumumab plus cyclophosphamide, bortezomib, dexamethasone was well-tolerated and effective in patients with newly diagnosed or relapsed/refractory multiple myeloma. Read More ›

Patient and caregiver preferences are important factors in selecting treatments. Read More ›

Better understanding of physician decision factors when selecting therapy for patients with refractory multiple myeloma may facilitate adoption of a wider variety of new treatment options. Read More ›

Subanalysis strongly supports the use of isatuximab plus carfilzomib and dexamethasone regardless of prior lines of therapy or refractory status to lenalidomide and bortezomib. Read More ›

Integrating a pharmacist into the care team can have substantial clinical and financial benefits in the setting of relapsed/refractory multiple myeloma and anti-CD38 antibodies. Read More ›